Peer-Firozjaei Milad, Tajik-Mansoury Mohammad Ali, Geramifar Parham, Ghorbani Raheb, Zarifi Shiva, Miller Cassandra, Rahmim Arman
Department of Medical Physics, Faculty of Medicine, Semnan University of Medical Sciences, Semnan.
Department of Biomedical Engineering and Medical Physics, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran.
Nucl Med Commun. 2022 Jun 1;43(6):646-655. doi: 10.1097/MNM.0000000000001546. Epub 2022 Mar 7.
There is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of 90Y and 177Lu-labeled peptides. Given the presence of different tumor sizes in patients and differing radionuclide dose delivery properties, the present study aims to use Monte Carlo simulations to estimate S-values to spherical tumors of various sizes with 90Y and 177Lu separately and in combination. The goal is to determine ratios of 90Y to 177Lu that result in the largest absorbed doses per decay of the radionuclides and the most suitable dose profiles to treat tumors of specific sizes.
Particle transfer calculations and simulations were performed using the Monte Carlo GATE simulation software. Spherical tumors of different sizes, ranging from 0.5 to 20 mm in radius, were designed. Activities of 177Lu and 90Y, individually and in combination, were homogeneously placed within the total volume of the tumors. We determined the S-values to the tumors, and to the external volume outside of the tumors (cross-dose) which was used to approximate background tissue. The dose profiles were obtained for each of the different tumor sizes, and the uniformity of dose within each tumor was calculated.
For all tumor sizes, the self-dose and cross-dose per decay from 90Y were higher than that from 177Lu. We observed that 177Lu had the most uniform dose distribution within tumors with radii less than 5 mm. For tumors greater than 5 mm in radius, a ratio of 25% 90Y to 75% 177Lu resulted in the most uniform doses. When the ratio of 177Lu to 90Y was smaller, the uniformity improved more with increasing tumor size. The cross-dose stayed approximately constant for tumors larger than 15 mm for all ratios of 177Lu to 90Y. Finally, as the size of the tumor increased, differences in the S-values between different ratios of 177Lu to 90Y decreased.
Our work showed that to achieve a more uniform dose distribution within the tumor, 177Lu alone is more effective for small tumors. For medium and large tumors, a ratio of 90Y to 177Lu with more or less 177Lu, respectively, is recommended.
使用90Y和177Lu标记的肽中的一种或两种,通过肽受体放射性核素疗法(PRRT)治疗神经内分泌肿瘤具有重大的研究意义和潜力。鉴于患者体内存在不同大小的肿瘤以及放射性核素剂量传递特性的差异,本研究旨在利用蒙特卡罗模拟分别及联合估算90Y和177Lu对各种大小球形肿瘤的S值。目的是确定能使放射性核素每次衰变产生最大吸收剂量的90Y与177Lu的比例,以及治疗特定大小肿瘤的最合适剂量分布。
使用蒙特卡罗GATE模拟软件进行粒子传输计算和模拟。设计了半径从0.5至20毫米不等的不同大小的球形肿瘤。将177Lu和90Y的活度单独及联合均匀置于肿瘤的总体积内。我们确定了肿瘤以及肿瘤外部体积(交叉剂量,用于近似背景组织)的S值。针对每种不同大小的肿瘤获取剂量分布,并计算每个肿瘤内剂量的均匀性。
对于所有肿瘤大小,90Y每次衰变的自剂量和交叉剂量均高于177Lu。我们观察到,177Lu在半径小于5毫米的肿瘤内具有最均匀的剂量分布。对于半径大于5毫米的肿瘤,90Y占25%与177Lu占75%的比例产生最均匀的剂量。当177Lu与90Y的比例较小时,随着肿瘤大小增加,均匀性改善得更多。对于所有177Lu与90Y的比例,对于半径大于15毫米的肿瘤,交叉剂量大致保持恒定。最后,随着肿瘤大小增加,177Lu与90Y不同比例之间的S值差异减小。
我们的研究表明,为在肿瘤内实现更均匀的剂量分布,单独使用177Lu对小肿瘤更有效。对于中大型肿瘤,建议90Y与177Lu的比例分别为或多或少含有更多的177Lu。